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Introduction 
Members of the zygomycete order Mucorales (Absidia, 
Cunninghamella, Mucor, Rhizomucor, Rhizopus) (Zygomycota) have 
medical, industrial, biotechnological and agricultural importance. 
Some isolates may cause post-harvest damages in agriculture, others 
are known as opportunistic pathogens whereas some members are 
used as producers of extracellular enzymes, organic acids and 
carotenoids. Based on their specific morphogenesis and sexual 
processes they are often investigated filamentous fungi. Members of 
the thermophilic Rhizomucor genus (R. miehei and R. pusillus) are 
practically important. In immunocompromised patient with leukemia, 
ketoacidosis, or serious skin injuries they can develop opportunistic 
fungal infections. On account of their thermophylic nature they can 
grow fast in humans. The therapy of zygomycoses is still limited 
because of the intrinsic resistance of these fungi to the majority of the 
currently used antimycotics. The most effective agents are 
amphothericin B and a new azole drug, posaconazole. In the cases of 
the other antifungal agents (like echinocandins, fluconazole, 
voriconazole or itraconazole) significant effect on pathogen 
zygomycetes has not been reported. 
The enzyme encoded by the hmgR gene catalyses the 
formation of mevalonate, which is a rate limiting step of the 
acetate/mevalonate (AMV) pathway leading to the isoprenoid 
synthesis. In eukaryotes, the AMV pathway regulates the 
biosynthesis of some hormones (gibberellins, steroids and some 
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mating factors), pigments, carotenoids and important components of 
the cell membrane, like sterol or ergosterol. The investigation of the 
genes involved in the biosynthesis of carotenoids has great 
biotechnological importance. There is currently an increasing interest 
in fungal sources of carotenoids, which requires the development of 
novel strategies to improve the production. The progress in the 
cloning of the carotenogenic genes opens up the possibility of 
modifying and engineering the carotenoid pathway in fungi. One of 
these important sources is Xanthophyllomyces dendrorhous producer 
of astaxanthin, a valuable oxygenated β-carotene derivative, which is 
used in the food, cosmetic and pharmaceutical industry and as feed 
colour additive (especially to salmons, trout and poultry). Mevalonate 
pathway also provides prenyl and farnesyl groups necessary for the 
normal function of many indispensable proteins (e.g. Ras and Rho) of 
the cell. Blockade of these processes through the inhibition of HMG-
CoA reductase decrease the growing rate, disturb the sporangiospore 
formation and cause morphogenetic changes and apoptosis in fungal 
cells. Statins are the widely known selective inhibitors of the HMG-
CoA reductase. They are commonly used as cholesterol lowering 
agents in human diseases. The pleiotropic effects of statins in human 
illnesses are intensively investigated today.  
The aim of our study was to isolate and characterize the 3-
hydroxy-3-methilglutaryl-coenzyme A reductase (HMG-CoA 
reductase) encoding gene in the practically important zygomycete 
fungus R. miehei, and to start the identification of the same gene in 
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the astaxanthin-producing yeast X. dendrorhous. In connection with 
that, the effect of statins as HMG-CoA reductase inhibitors on 
opportunistic pathogen zygomycetes fungi was investigated. The 
interaction between amphotericin B and two statins, fluvastatin and 
rosuvastatin, was also tested in vitro in terms of growing inhibition of 
fungi. 
Aims 
In the recent years, incidence of zygomycoses has increased 
on account of the growing number of endangered patients. The 
therapy provided by newer and available antifungal agents is not 
sufficient for managing these specific infections. Molecular 
investigations of Zygomycetes can yield new and better therapy 
targets; however, because of the peculiarity of this fungal group, their 
study can be hardly replaced with the research of other fungi. For the 
development of a more efficient genetic transformation system of 
these fungi their molecular characterization is also indispensable. 
Taking into account all these considerations, the aims of our 
study were the followings: 
• Cloning and identification of the gene encoding the HMG-
CoA reductase of R. miehei. Starting experiments for the 
identification of hmgR gene of X. dendrorhous. 
• Characterization of the gene and the corresponding amino 
acid sequence, additionally, determination of the copy 
number of the gene in the R. miehei genome. 
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• Transformation of the identified gene into an appropiate 
zygomycete fungus and investigation of its effect on the 
host’s susceptibility to statins. The purpose of these 
experiments was to examine the potential applicability of the 
hmgR gene in a new transformation and selection system for 
zygomycetes fungi.  
• Investigation of the biological effect of the selective 
inhibitors of the enzyme (statins).  
• Analysis of the in vitro susceptibility of several zygomycetes 
species to amphotericin B in combination with fluvastatin 
and rosuvastatin. 
 
Methods 
Screening of phage genome library: 
• amplification of phages 
• plaque-hybridization 
• phage DNA purification 
Molecular manipulation methods: 
• DNA, RNA isolation 
• polymerase chain reaction (PCR) 
• reverse transcription (RT-PCR) 
• Southern-blot 
• DNA fragment isolation and molecular cloning 
• plasmid transformation and plasmid preparation of E. coli 
Analysis of sequence data of DNA and protein: 
• BLAST 
• ClustalW 
• contig assembly program, CAP 
Transformation of filamentous fungi: 
• protoplast preparation 
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• PEG-mediated transformation 
• Susceptibility testing of antifungal agents (in vitro) 
• Testing of the interaction of antifungal agents (in vitro) 
 
Results 
 
Identification and characterization of the hmgR gene 
Degenerated PCR primers were designed to the most conserved 
region of hmgR genes, and the resulted PCR fragment was used as 
homologous probe for screening the lambda Fix II phage library of R. 
miehei genome. The R. miehei hmgR gene was identified and cloned 
into pBluescript vector. The entire gene sequence (4977 bp) was 
determined. Five introns were found in the hmgR gene and a putative 
1058 amino acids correspond to the nucleotide sequence. The 
similarity of R. miehei hmgR gene with that of other fungi and 
eukaryotes was investigated. It was found that four introns of R. 
miehei hmgR are in the same position with all four introns of 
Phycomyces blakesleeanus. Partial sequence (315 bp) of the X. 
dendrorhous hmgR gene encoding the catalytic region (105 aa) of 
HMG-CoA reductase was cloned and sequence motifs responsible for 
the substrate binding were identified. 
The analysis of the amino acid sequence of the encoded protein 
of R. miehei and the determined partial sequence of X. dendrorhous 
revealed the conserved catalytic domain, which is highly similar to 
other described HMG-CoA reductases. Motifs playing role in the 
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NADP and the HMG binding show 100% similarity among fungi. 
Like in other organisms, the N-terminal region of the proteins shows 
variability. 
Fungal and plant genomes, frequently contain two or more 
hmgR genes which may differ in their expression. Southern-blot 
analysis revealed that R. miehei, similarly to P. blakesleeanus, 
contains only one hmgR gene. It was proved by RT-PCR experiments 
that the isolated R. miehei hmgR gene is expressed in the fungus. 
 
Transformation experiments in the zygomycete fungus 
Mucor circinelloides 
The green fluorescent protein gene (gfp) under the control of the 
promoter of the R. miehei hmgR gene (642 bps) was successfully 
transformed into Mucor circinelloides. The promoter of R. miehei 
hmgR gene was able to drive the expression of the gfp in the 
transformants, which was proved by fluorescence microscopy. 
A vector harbouring the entire hmgR gene of R. miehei (4656 
bps) was also introduced into the zygomycete fungus M. 
circinelloides. The yielded transformant was shown to have better 
tolerance to fluvastatin, the competitive inhibitor of HMG-CoA 
reductase. In our experiments the growing of the control strain was 
inhibited at 4 µg/ml of fluvastatin while the transformant showed 
40% of growing compared with its growing in the fluvastatin-free 
medium. Based on that increased resistance a transformation 
selection method can be elaborated. 
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Susceptibility testing of various statins on zygomycetes fungi 
 
Susceptibility to lovastatin of 27 R. miehei and R. pusillus 
isolates was investigated. It was demonstrated that in acidic pH (pH 
4) or with usage of minimal medium and smaller inoculum size, 
inhibition of growing triggered by lovastatin is stronger. Based on the 
significantly higher sensitivity of R. pusillus to lovastatin than that of 
R. miehei, a simple and reliable method for species-level 
differentiation was elaborated. It is supposed that besides the 
susceptibility to lovastatin, the two Rhizomucor species are different 
in their susceptibility to other antifungal agents also.  
In other experiments, susceptibility of 7 opportunistic pathogen 
species, R. miehei, R. pusillus, Absidia corymbifera, Mortierella 
wolfii, Syncephalastrum racemosum, Rhizopus oryzae, Rhizopus 
microsporus var. rhizopodiformis to various statins was tested. 
Commercially available statins (lovastatin, simvastatin, rosuvastatin, 
atorvastatin, fluvastatin, pravastatin) used as cholesterol-lowering 
agents in human vascular diseases were involved in these 
experiments. It was found that the susceptibility of the different 
species is different. The most resistant strain to statins was M. wolfii, 
while the most sensitive were R. pusillus and A. corymbifera in the in 
vitro susceptibility testing. The order of the inhibition efficiency 
among the various statins was also different in the isolates. In the 
background of this phenomenon, besides the differences in the 
structure and solubility of the statin molecules, there might be the 
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differences in the cell-structure or other molecular alterations. These 
differences can also influence the success of the therapy against these 
fungi with the known antifungal agents. 
The potential synergy of fluvastatin and rosuvastatin with 
amphotericin B was also tested in growth inhibition of opportunistic 
pathogen zygomycetes fungi. Amphotericin B is one of the most 
effective antifungal agents against zygomycoses. It was shown that 1 
µg/ml amphotericin B caused 75% growth inhibition in most of the 
examined isolates. The only exception was Mortierella wolfii, in case 
of that the highest concentration of amphotericin B (16 µg/ml) caused 
50% inhibition. At the combination of the highest concentration of 
amphotericin B (16 µg/ml) and the highest concentration of 
fluvastatin (96 µg/ml), the growth inhibition was more than 75%. 
Statins used in combination with amphotericin B exerted additive 
effect on the majority of the examined isolates; in some cases, 
synergism was also detected. 
 
Summary 
In our experiments, the entire R. miehei hmgR gene and a partial 
hmgR gene of the X. dendrorhous were identified and characterized. 
Using the isolated gene, two vectors were constructed and 
successfully transformed into M. circinelloides MS12 strain. It was 
shown that the promoter of R. miehei hmgR gene was able to driven 
the production of functional GFP in M. circinelloides. It was also 
proved that transformation with the entire hmgR gene provides higher 
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resistance to fluvastatin due to the gene dose effect. Based on that 
result a new transformational selection system can be developed in 
zygomycetous fungi. 
Susceptibility of 27 R. miehei and R. pusillus isolates to 
lovastatin was investigated, and effect of the culturing conditions 
(e.g. pH, composition of the medium and inoculum size) on the 
susceptibility testing was also examined. Based on these results, a 
simple method was elaborated for reliable differentiation of the 
Rhizomucor species. 
Furthermore, sensitivity of 7 opportunistic pathogen fungi (R. 
miehei, R. pusillus, A. corymbifera, M. wolfii, S. racemosum, Rh. 
oryzae, Rh. microsporus var. rhizopodioirmis) to statins (lovastatin, 
simvastatin, rosuvastatin, atorvastatin, pravastatin, fluvastatin) 
presently known as cholesterol lowering agents in medicine was 
demonstrated. Combinations of fluvastatin and rosuvastatin with 
amphotericin B had additive effect on fungal growth whereas in some 
cases, synergism was also observed. 
We can conclude that in the increasing number of zygomycoses, 
usage of statins in combination with other antifungal drugs can 
provide an effective therapy of these infections. It can also decrease 
the occurrence of serious side-effects of the currently used antifungal 
agents and minimize the possibility of the emergence of drug-
resistance. 
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